2020
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. The BMJ 2020, 368: l7078. PMID: 32024657, PMCID: PMC7190063, DOI: 10.1136/bmj.l7078.Peer-Reviewed Original ResearchConceptsIndividual patient-level dataCardiovascular related deathsCardiovascular riskMyocardial infarctionRelated deathsSummary-level dataHeart failureOdds ratioSystematic reviewIncreased cardiovascular riskMore myocardial infarctionsHeart failure eventsCochrane Central RegistryAcute myocardial infarctionMyocardial infarction eventsPatient-level dataRandom-effects modelWeb of ScienceAnalysis of trialsEligible trialsComposite outcomeAdverse eventsContinuity correctionControlled TrialsRosiglitazone treatment
2002
The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF. The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes. Diabetes 2002, 51: 797-802. PMID: 11872682, PMCID: PMC2995527, DOI: 10.2337/diabetes.51.3.797.Peer-Reviewed Original ResearchMeSH KeywordsAdipocytesAdipose TissueBlood GlucoseBody CompositionCalorimetry, IndirectDiabetes Mellitus, Type 2Fatty AcidsGlucose Clamp TechniqueGlycated HemoglobinGlycerolHumansHyperinsulinismInsulinKineticsLipidsLipolysisLiverMagnetic Resonance SpectroscopyMicrodialysisMiddle AgedMuscle, SkeletalOxidation-ReductionRosiglitazoneThiazolesThiazolidinedionesTriglyceridesConceptsPlasma fatty acid concentrationsMuscle triglyceride contentEffects of rosiglitazoneType 2 diabetesInsulin sensitivityPeripheral adipocytesTriglyceride contentRosiglitazone treatmentFatty acid concentrationsTwo-step hyperinsulinemic-euglycemic clampSkeletal muscle triglyceride contentType 2 diabetic subjectsInsulin-stimulated glucose metabolismWhole-body insulin sensitivityExtramyocellular lipid contentInsulin-responsive organHepatic triglyceride contentHyperinsulinemic-euglycemic clampAdipocyte insulin sensitivityDiabetic subjectsInsulin clampGlucose metabolismGlycerol releaseResponsive organSubcutaneous fat
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply